As I write this editorial, we are still in the midst of the COVID-19 pandemic, headed into the third wave. I am impressed at how well our educational community has adapted to online learning, and it has been nice to see colleagues and to learn through a virtual platform. I am looking forward to being able to see colleagues in person again, but technology has helped us bridge the gap.

One thing that is becoming clear to me is that it is a very good time for us to take a comprehensive look at our practice and see what improvements we can make. This issue of Glaucoma Physician takes a fully comprehensive look at glaucoma and its treatment. Along those lines, I had a major milestone in surgery last week, performing my first full day of cataract and glaucoma surgery after which no patients will require postoperative antibiotic or anti-inflammatory therapies. A combination of intravitreal triamcinolone and moxifloxacin, Dextenza (Ocular Therapeutix), and Dexycu (Eyepoint Pharmaceuticals) with intracameral moxifloxacin helped get each case the appropriate sustained therapy. Michael Greenwood, MD, covers this topic in this issue, and Jason Bacharach, MD, discusses compliance and the value of nonpreserved drops and fixed-combination therapies. Along the lines of challenging therapeutic scenarios, Marlene Moster, MD, and Robert Purgert, MD, PhD, have written a fantastic review of glaucoma management in the pregnant patient.

Addressing our field’s recent emphasis on outflow, Brian Nguyen and Sahar Bedrood, MD, PhD, take a look at aqueous-humor outflow through the meshwork, and Jody Piltz-Seymour, MD, and Monisha Vora, MD, describe its ultimate destination, the episcleral venous system, to help us understand the tissue we are treating both pharmacologically and surgically. However, we still haven’t given up on the supraciliary outflow pathway, and Steven Vold, MD, and Brittany Perzia take us through a review of existing and possible new treatments for this tissue.

As I review the contents of this issue, I am comforted to know that there is still plenty about glaucoma we have to learn, and now is a great time to do it. We here at Glaucoma Physician hope that you find this issue to be a helpful and pleasantly distracting way of taking advantage of an opportunity to learn as we wait for the pandemic to end. GP

Dr. Radcliffe is a clinical associate professor of ophthalmology at the New York Eye and Ear Infirmary of Mount Sinai and a surgeon at the New York Eye Surgery Center.